nodes	percent_of_prediction	percent_of_DWPC	metapath
Boceprevir—CMA1—hematologic cancer	0.368	0.924	CbGaD
Boceprevir—ABCB1—hematologic cancer	0.0304	0.0763	CbGaD
Boceprevir—ABCB1—Lenalidomide—hematologic cancer	0.0137	0.0494	CbGbCtD
Boceprevir—CYP3A5—Daunorubicin—hematologic cancer	0.0123	0.0445	CbGbCtD
Boceprevir—CYP3A5—Thalidomide—hematologic cancer	0.0112	0.0405	CbGbCtD
Boceprevir—CYP3A5—Teniposide—hematologic cancer	0.0107	0.0387	CbGbCtD
Boceprevir—CYP3A5—Ifosfamide—hematologic cancer	0.00989	0.0357	CbGbCtD
Boceprevir—CYP3A5—Imatinib—hematologic cancer	0.00944	0.0341	CbGbCtD
Boceprevir—CYP3A4—Bexarotene—hematologic cancer	0.0082	0.0296	CbGbCtD
Boceprevir—ABCB1—Daunorubicin—hematologic cancer	0.00802	0.029	CbGbCtD
Boceprevir—ABCB1—Alitretinoin—hematologic cancer	0.00786	0.0284	CbGbCtD
Boceprevir—CYP3A4—Busulfan—hematologic cancer	0.00762	0.0275	CbGbCtD
Boceprevir—CYP3A4—Lomustine—hematologic cancer	0.00762	0.0275	CbGbCtD
Boceprevir—CYP3A5—Dasatinib—hematologic cancer	0.00758	0.0274	CbGbCtD
Boceprevir—CYP3A4—Thiotepa—hematologic cancer	0.00679	0.0245	CbGbCtD
Boceprevir—ABCB1—Imatinib—hematologic cancer	0.00615	0.0222	CbGbCtD
Boceprevir—CYP3A5—Irinotecan—hematologic cancer	0.0059	0.0213	CbGbCtD
Boceprevir—ABCB1—Nilotinib—hematologic cancer	0.00559	0.0202	CbGbCtD
Boceprevir—ABCB1—Vinorelbine—hematologic cancer	0.00554	0.02	CbGbCtD
Boceprevir—CYP3A4—Methoxsalen—hematologic cancer	0.00528	0.0191	CbGbCtD
Boceprevir—CYP3A5—Vincristine—hematologic cancer	0.00516	0.0186	CbGbCtD
Boceprevir—CYP3A4—Bortezomib—hematologic cancer	0.00503	0.0181	CbGbCtD
Boceprevir—ABCB1—Dasatinib—hematologic cancer	0.00494	0.0178	CbGbCtD
Boceprevir—ABCB1—Mitoxantrone—hematologic cancer	0.00488	0.0176	CbGbCtD
Boceprevir—CYP3A4—Daunorubicin—hematologic cancer	0.00481	0.0174	CbGbCtD
Boceprevir—CYP3A5—Etoposide—hematologic cancer	0.00472	0.0171	CbGbCtD
Boceprevir—ABCB1—Betamethasone—hematologic cancer	0.00435	0.0157	CbGbCtD
Boceprevir—ABCB1—Gemcitabine—hematologic cancer	0.00431	0.0156	CbGbCtD
Boceprevir—ABCB1—Prednisolone—hematologic cancer	0.00429	0.0155	CbGbCtD
Boceprevir—CYP3A4—Cytarabine—hematologic cancer	0.00424	0.0153	CbGbCtD
Boceprevir—CYP3A4—Teniposide—hematologic cancer	0.00418	0.0151	CbGbCtD
Boceprevir—ABCB1—Prednisone—hematologic cancer	0.00405	0.0146	CbGbCtD
Boceprevir—CYP3A5—Dexamethasone—hematologic cancer	0.00388	0.014	CbGbCtD
Boceprevir—CYP3A4—Ifosfamide—hematologic cancer	0.00385	0.0139	CbGbCtD
Boceprevir—ABCB1—Irinotecan—hematologic cancer	0.00384	0.0139	CbGbCtD
Boceprevir—CYP3A4—Imatinib—hematologic cancer	0.00368	0.0133	CbGbCtD
Boceprevir—CYP3A4—Ruxolitinib—hematologic cancer	0.00347	0.0125	CbGbCtD
Boceprevir—ABCB1—Vinblastine—hematologic cancer	0.00341	0.0123	CbGbCtD
Boceprevir—ABCB1—Vincristine—hematologic cancer	0.00336	0.0121	CbGbCtD
Boceprevir—CYP3A4—Nilotinib—hematologic cancer	0.00335	0.0121	CbGbCtD
Boceprevir—CYP3A4—Vinorelbine—hematologic cancer	0.00332	0.012	CbGbCtD
Boceprevir—Telaprevir—CMA1—hematologic cancer	0.00322	0.855	CrCbGaD
Boceprevir—ABCB1—Cisplatin—hematologic cancer	0.00313	0.0113	CbGbCtD
Boceprevir—ABCB1—Etoposide—hematologic cancer	0.00307	0.0111	CbGbCtD
Boceprevir—CYP3A4—Triamcinolone—hematologic cancer	0.00303	0.011	CbGbCtD
Boceprevir—CYP3A4—Dasatinib—hematologic cancer	0.00296	0.0107	CbGbCtD
Boceprevir—CYP3A4—Mitoxantrone—hematologic cancer	0.00292	0.0105	CbGbCtD
Boceprevir—CTSV—hematopoietic system—hematologic cancer	0.00291	0.062	CbGeAlD
Boceprevir—CMA1—hematopoietic system—hematologic cancer	0.00278	0.0592	CbGeAlD
Boceprevir—CYP3A4—Betamethasone—hematologic cancer	0.0026	0.0094	CbGbCtD
Boceprevir—CYP3A4—Prednisolone—hematologic cancer	0.00257	0.00928	CbGbCtD
Boceprevir—ABCB1—Dexamethasone—hematologic cancer	0.00253	0.00913	CbGbCtD
Boceprevir—CYP3A4—Prednisone—hematologic cancer	0.00243	0.00876	CbGbCtD
Boceprevir—CTSL—hematopoietic system—hematologic cancer	0.00237	0.0506	CbGeAlD
Boceprevir—CYP3A4—Irinotecan—hematologic cancer	0.0023	0.0083	CbGbCtD
Boceprevir—CTSV—gonad—hematologic cancer	0.00221	0.0471	CbGeAlD
Boceprevir—ABCB1—Doxorubicin—hematologic cancer	0.0021	0.00757	CbGbCtD
Boceprevir—CYP3A4—Vinblastine—hematologic cancer	0.00204	0.00738	CbGbCtD
Boceprevir—ABCB1—Methotrexate—hematologic cancer	0.00203	0.00734	CbGbCtD
Boceprevir—CYP3A4—Vincristine—hematologic cancer	0.00201	0.00726	CbGbCtD
Boceprevir—CYP3A4—Etoposide—hematologic cancer	0.00184	0.00665	CbGbCtD
Boceprevir—CMA1—blood—hematologic cancer	0.00184	0.0392	CbGeAlD
Boceprevir—CTSL—gonad—hematologic cancer	0.00181	0.0385	CbGeAlD
Boceprevir—CTSK—hematopoietic system—hematologic cancer	0.00179	0.0381	CbGeAlD
Boceprevir—CMA1—bone marrow—hematologic cancer	0.00178	0.0379	CbGeAlD
Boceprevir—CTSV—lung—hematologic cancer	0.00169	0.036	CbGeAlD
Boceprevir—CMA1—lung—hematologic cancer	0.00161	0.0344	CbGeAlD
Boceprevir—CTSV—testis—hematologic cancer	0.00159	0.034	CbGeAlD
Boceprevir—CTSL—blood—hematologic cancer	0.00157	0.0335	CbGeAlD
Boceprevir—CTSS—hematopoietic system—hematologic cancer	0.00157	0.0334	CbGeAlD
Boceprevir—CTSL—bone marrow—hematologic cancer	0.00152	0.0325	CbGeAlD
Boceprevir—CYP3A4—Dexamethasone—hematologic cancer	0.00151	0.00547	CbGbCtD
Boceprevir—CTSL—lung—hematologic cancer	0.00138	0.0294	CbGeAlD
Boceprevir—CTSK—gonad—hematologic cancer	0.00136	0.029	CbGeAlD
Boceprevir—CTSL—testis—hematologic cancer	0.0013	0.0277	CbGeAlD
Boceprevir—CYP3A4—Doxorubicin—hematologic cancer	0.00126	0.00454	CbGbCtD
Boceprevir—CTSS—gonad—hematologic cancer	0.00119	0.0254	CbGeAlD
Boceprevir—CTSK—blood—hematologic cancer	0.00119	0.0253	CbGeAlD
Boceprevir—CTSK—bone marrow—hematologic cancer	0.00115	0.0245	CbGeAlD
Boceprevir—CMA1—lymph node—hematologic cancer	0.0011	0.0235	CbGeAlD
Boceprevir—CTSK—lung—hematologic cancer	0.00104	0.0222	CbGeAlD
Boceprevir—CTSS—blood—hematologic cancer	0.00104	0.0221	CbGeAlD
Boceprevir—CTSS—bone marrow—hematologic cancer	0.00101	0.0214	CbGeAlD
Boceprevir—CTSK—testis—hematologic cancer	0.000981	0.0209	CbGeAlD
Boceprevir—CTSL—lymph node—hematologic cancer	0.000943	0.0201	CbGeAlD
Boceprevir—CTSS—lung—hematologic cancer	0.000911	0.0194	CbGeAlD
Boceprevir—CTSS—testis—hematologic cancer	0.000859	0.0183	CbGeAlD
Boceprevir—CTSK—lymph node—hematologic cancer	0.000711	0.0152	CbGeAlD
Boceprevir—CTSS—lymph node—hematologic cancer	0.000623	0.0133	CbGeAlD
Boceprevir—CYP3A5—hematopoietic system—hematologic cancer	0.000521	0.0111	CbGeAlD
Boceprevir—CYP3A4—hematopoietic system—hematologic cancer	0.000391	0.00833	CbGeAlD
Boceprevir—CYP3A5—blood—hematologic cancer	0.000345	0.00735	CbGeAlD
Boceprevir—CYP3A5—lung—hematologic cancer	0.000302	0.00645	CbGeAlD
Boceprevir—Telaprevir—ALB—hematologic cancer	0.000278	0.074	CrCbGaD
Boceprevir—ABCB1—hematopoietic system—hematologic cancer	0.000277	0.0059	CbGeAlD
Boceprevir—Telaprevir—ABCB1—hematologic cancer	0.000266	0.0707	CrCbGaD
Boceprevir—CYP3A4—blood—hematologic cancer	0.000259	0.00552	CbGeAlD
Boceprevir—CTSL—Fluticasone Propionate—Dexamethasone—hematologic cancer	0.000242	0.146	CbGdCrCtD
Boceprevir—CTSL—Fluticasone Propionate—Betamethasone—hematologic cancer	0.000242	0.146	CbGdCrCtD
Boceprevir—CTSL—Fluticasone Propionate—Triamcinolone—hematologic cancer	0.000236	0.143	CbGdCrCtD
Boceprevir—ABCB1—gonad—hematologic cancer	0.00021	0.00448	CbGeAlD
Boceprevir—ABCB1—blood—hematologic cancer	0.000183	0.00391	CbGeAlD
Boceprevir—ABCB1—bone marrow—hematologic cancer	0.000177	0.00378	CbGeAlD
Boceprevir—ABCB1—lung—hematologic cancer	0.000161	0.00342	CbGeAlD
Boceprevir—ABCB1—testis—hematologic cancer	0.000152	0.00323	CbGeAlD
Boceprevir—CTSL—Dexamethasone—Betamethasone—hematologic cancer	0.000123	0.0741	CbGdCrCtD
Boceprevir—CTSL—Betamethasone—Dexamethasone—hematologic cancer	0.000123	0.0741	CbGdCrCtD
Boceprevir—CTSL—Betamethasone—Triamcinolone—hematologic cancer	0.00012	0.0724	CbGdCrCtD
Boceprevir—CTSL—Dexamethasone—Triamcinolone—hematologic cancer	0.00012	0.0724	CbGdCrCtD
Boceprevir—CTSL—Dexamethasone—Prednisone—hematologic cancer	0.000114	0.0687	CbGdCrCtD
Boceprevir—CTSL—Betamethasone—Prednisone—hematologic cancer	0.000114	0.0687	CbGdCrCtD
Boceprevir—CTSL—Betamethasone—Prednisolone—hematologic cancer	0.000111	0.0671	CbGdCrCtD
Boceprevir—CTSL—Dexamethasone—Prednisolone—hematologic cancer	0.000111	0.0671	CbGdCrCtD
Boceprevir—ABCB1—lymph node—hematologic cancer	0.00011	0.00234	CbGeAlD
Boceprevir—Vomiting—Cisplatin—hematologic cancer	9.55e-06	5.46e-05	CcSEcCtD
Boceprevir—Hyperhidrosis—Prednisone—hematologic cancer	9.53e-06	5.45e-05	CcSEcCtD
Boceprevir—Vision blurred—Methotrexate—hematologic cancer	9.51e-06	5.44e-05	CcSEcCtD
Boceprevir—Mental disorder—Epirubicin—hematologic cancer	9.51e-06	5.44e-05	CcSEcCtD
Boceprevir—Erythema multiforme—Doxorubicin—hematologic cancer	9.5e-06	5.43e-05	CcSEcCtD
Boceprevir—Rash—Cisplatin—hematologic cancer	9.47e-06	5.41e-05	CcSEcCtD
Boceprevir—Dermatitis—Cisplatin—hematologic cancer	9.46e-06	5.41e-05	CcSEcCtD
Boceprevir—Malnutrition—Epirubicin—hematologic cancer	9.45e-06	5.4e-05	CcSEcCtD
Boceprevir—Erythema—Epirubicin—hematologic cancer	9.45e-06	5.4e-05	CcSEcCtD
Boceprevir—Diarrhoea—Etoposide—hematologic cancer	9.41e-06	5.38e-05	CcSEcCtD
Boceprevir—Eye disorder—Doxorubicin—hematologic cancer	9.38e-06	5.37e-05	CcSEcCtD
Boceprevir—Ill-defined disorder—Methotrexate—hematologic cancer	9.37e-06	5.36e-05	CcSEcCtD
Boceprevir—Tinnitus—Doxorubicin—hematologic cancer	9.36e-06	5.35e-05	CcSEcCtD
Boceprevir—Anaemia—Methotrexate—hematologic cancer	9.33e-06	5.33e-05	CcSEcCtD
Boceprevir—Feeling abnormal—Betamethasone—hematologic cancer	9.33e-06	5.33e-05	CcSEcCtD
Boceprevir—Feeling abnormal—Dexamethasone—hematologic cancer	9.33e-06	5.33e-05	CcSEcCtD
Boceprevir—Cardiac disorder—Doxorubicin—hematologic cancer	9.32e-06	5.33e-05	CcSEcCtD
Boceprevir—Flushing—Doxorubicin—hematologic cancer	9.32e-06	5.33e-05	CcSEcCtD
Boceprevir—Flatulence—Epirubicin—hematologic cancer	9.31e-06	5.32e-05	CcSEcCtD
Boceprevir—Gastrointestinal pain—Dexamethasone—hematologic cancer	9.26e-06	5.29e-05	CcSEcCtD
Boceprevir—Gastrointestinal pain—Betamethasone—hematologic cancer	9.26e-06	5.29e-05	CcSEcCtD
Boceprevir—Dysgeusia—Epirubicin—hematologic cancer	9.25e-06	5.29e-05	CcSEcCtD
Boceprevir—Hypersensitivity—Triamcinolone—hematologic cancer	9.19e-06	5.26e-05	CcSEcCtD
Boceprevir—Back pain—Epirubicin—hematologic cancer	9.14e-06	5.22e-05	CcSEcCtD
Boceprevir—Angiopathy—Doxorubicin—hematologic cancer	9.11e-06	5.21e-05	CcSEcCtD
Boceprevir—Malaise—Methotrexate—hematologic cancer	9.1e-06	5.2e-05	CcSEcCtD
Boceprevir—Dizziness—Etoposide—hematologic cancer	9.1e-06	5.2e-05	CcSEcCtD
Boceprevir—Muscle spasms—Epirubicin—hematologic cancer	9.08e-06	5.19e-05	CcSEcCtD
Boceprevir—Immune system disorder—Doxorubicin—hematologic cancer	9.07e-06	5.19e-05	CcSEcCtD
Boceprevir—Vertigo—Methotrexate—hematologic cancer	9.07e-06	5.19e-05	CcSEcCtD
Boceprevir—Mediastinal disorder—Doxorubicin—hematologic cancer	9.05e-06	5.17e-05	CcSEcCtD
Boceprevir—Leukopenia—Methotrexate—hematologic cancer	9.04e-06	5.17e-05	CcSEcCtD
Boceprevir—Chills—Doxorubicin—hematologic cancer	9.01e-06	5.15e-05	CcSEcCtD
Boceprevir—Urticaria—Dexamethasone—hematologic cancer	8.99e-06	5.14e-05	CcSEcCtD
Boceprevir—Urticaria—Betamethasone—hematologic cancer	8.99e-06	5.14e-05	CcSEcCtD
Boceprevir—Musculoskeletal discomfort—Prednisone—hematologic cancer	8.98e-06	5.14e-05	CcSEcCtD
Boceprevir—Dizziness—Prednisolone—hematologic cancer	8.97e-06	5.13e-05	CcSEcCtD
Boceprevir—Arrhythmia—Doxorubicin—hematologic cancer	8.97e-06	5.13e-05	CcSEcCtD
Boceprevir—Asthenia—Triamcinolone—hematologic cancer	8.95e-06	5.12e-05	CcSEcCtD
Boceprevir—Abdominal pain—Betamethasone—hematologic cancer	8.95e-06	5.12e-05	CcSEcCtD
Boceprevir—Abdominal pain—Dexamethasone—hematologic cancer	8.95e-06	5.12e-05	CcSEcCtD
Boceprevir—Body temperature increased—Betamethasone—hematologic cancer	8.95e-06	5.12e-05	CcSEcCtD
Boceprevir—Body temperature increased—Dexamethasone—hematologic cancer	8.95e-06	5.12e-05	CcSEcCtD
Boceprevir—Nausea—Cisplatin—hematologic cancer	8.92e-06	5.1e-05	CcSEcCtD
Boceprevir—Insomnia—Prednisone—hematologic cancer	8.92e-06	5.1e-05	CcSEcCtD
Boceprevir—Vision blurred—Epirubicin—hematologic cancer	8.9e-06	5.09e-05	CcSEcCtD
Boceprevir—Alopecia—Doxorubicin—hematologic cancer	8.87e-06	5.07e-05	CcSEcCtD
Boceprevir—Paraesthesia—Prednisone—hematologic cancer	8.85e-06	5.06e-05	CcSEcCtD
Boceprevir—Pruritus—Triamcinolone—hematologic cancer	8.83e-06	5.05e-05	CcSEcCtD
Boceprevir—Cough—Methotrexate—hematologic cancer	8.81e-06	5.04e-05	CcSEcCtD
Boceprevir—Mental disorder—Doxorubicin—hematologic cancer	8.8e-06	5.03e-05	CcSEcCtD
Boceprevir—Ill-defined disorder—Epirubicin—hematologic cancer	8.77e-06	5.01e-05	CcSEcCtD
Boceprevir—Vomiting—Etoposide—hematologic cancer	8.75e-06	5e-05	CcSEcCtD
Boceprevir—Malnutrition—Doxorubicin—hematologic cancer	8.74e-06	5e-05	CcSEcCtD
Boceprevir—Erythema—Doxorubicin—hematologic cancer	8.74e-06	5e-05	CcSEcCtD
Boceprevir—Anaemia—Epirubicin—hematologic cancer	8.73e-06	4.99e-05	CcSEcCtD
Boceprevir—Agitation—Epirubicin—hematologic cancer	8.68e-06	4.96e-05	CcSEcCtD
Boceprevir—Dyspepsia—Prednisone—hematologic cancer	8.68e-06	4.96e-05	CcSEcCtD
Boceprevir—Rash—Etoposide—hematologic cancer	8.67e-06	4.96e-05	CcSEcCtD
Boceprevir—Dermatitis—Etoposide—hematologic cancer	8.67e-06	4.95e-05	CcSEcCtD
Boceprevir—Headache—Etoposide—hematologic cancer	8.62e-06	4.93e-05	CcSEcCtD
Boceprevir—Flatulence—Doxorubicin—hematologic cancer	8.61e-06	4.92e-05	CcSEcCtD
Boceprevir—Arthralgia—Methotrexate—hematologic cancer	8.6e-06	4.91e-05	CcSEcCtD
Boceprevir—Chest pain—Methotrexate—hematologic cancer	8.6e-06	4.91e-05	CcSEcCtD
Boceprevir—Myalgia—Methotrexate—hematologic cancer	8.6e-06	4.91e-05	CcSEcCtD
Boceprevir—Decreased appetite—Prednisone—hematologic cancer	8.57e-06	4.9e-05	CcSEcCtD
Boceprevir—Dysgeusia—Doxorubicin—hematologic cancer	8.56e-06	4.89e-05	CcSEcCtD
Boceprevir—Rash—Prednisolone—hematologic cancer	8.55e-06	4.89e-05	CcSEcCtD
Boceprevir—Dermatitis—Prednisolone—hematologic cancer	8.55e-06	4.89e-05	CcSEcCtD
Boceprevir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	8.54e-06	4.88e-05	CcSEcCtD
Boceprevir—Malaise—Epirubicin—hematologic cancer	8.52e-06	4.87e-05	CcSEcCtD
Boceprevir—Fatigue—Prednisone—hematologic cancer	8.5e-06	4.86e-05	CcSEcCtD
Boceprevir—Headache—Prednisolone—hematologic cancer	8.5e-06	4.86e-05	CcSEcCtD
Boceprevir—Discomfort—Methotrexate—hematologic cancer	8.49e-06	4.85e-05	CcSEcCtD
Boceprevir—Vertigo—Epirubicin—hematologic cancer	8.49e-06	4.85e-05	CcSEcCtD
Boceprevir—Syncope—Epirubicin—hematologic cancer	8.47e-06	4.84e-05	CcSEcCtD
Boceprevir—Leukopenia—Epirubicin—hematologic cancer	8.46e-06	4.83e-05	CcSEcCtD
Boceprevir—Back pain—Doxorubicin—hematologic cancer	8.46e-06	4.83e-05	CcSEcCtD
Boceprevir—Constipation—Prednisone—hematologic cancer	8.43e-06	4.82e-05	CcSEcCtD
Boceprevir—Muscle spasms—Doxorubicin—hematologic cancer	8.4e-06	4.8e-05	CcSEcCtD
Boceprevir—Palpitations—Epirubicin—hematologic cancer	8.35e-06	4.77e-05	CcSEcCtD
Boceprevir—Confusional state—Methotrexate—hematologic cancer	8.31e-06	4.75e-05	CcSEcCtD
Boceprevir—Loss of consciousness—Epirubicin—hematologic cancer	8.3e-06	4.75e-05	CcSEcCtD
Boceprevir—Dizziness—Triamcinolone—hematologic cancer	8.25e-06	4.72e-05	CcSEcCtD
Boceprevir—Cough—Epirubicin—hematologic cancer	8.24e-06	4.71e-05	CcSEcCtD
Boceprevir—Vision blurred—Doxorubicin—hematologic cancer	8.24e-06	4.71e-05	CcSEcCtD
Boceprevir—Infection—Methotrexate—hematologic cancer	8.19e-06	4.68e-05	CcSEcCtD
Boceprevir—Nausea—Etoposide—hematologic cancer	8.17e-06	4.67e-05	CcSEcCtD
Boceprevir—Hypertension—Epirubicin—hematologic cancer	8.16e-06	4.66e-05	CcSEcCtD
Boceprevir—Feeling abnormal—Prednisone—hematologic cancer	8.12e-06	4.64e-05	CcSEcCtD
Boceprevir—Asthenia—Betamethasone—hematologic cancer	8.12e-06	4.64e-05	CcSEcCtD
Boceprevir—Asthenia—Dexamethasone—hematologic cancer	8.12e-06	4.64e-05	CcSEcCtD
Boceprevir—Ill-defined disorder—Doxorubicin—hematologic cancer	8.11e-06	4.64e-05	CcSEcCtD
Boceprevir—Nervous system disorder—Methotrexate—hematologic cancer	8.08e-06	4.62e-05	CcSEcCtD
Boceprevir—Anaemia—Doxorubicin—hematologic cancer	8.08e-06	4.62e-05	CcSEcCtD
Boceprevir—Thrombocytopenia—Methotrexate—hematologic cancer	8.07e-06	4.61e-05	CcSEcCtD
Boceprevir—Gastrointestinal pain—Prednisone—hematologic cancer	8.06e-06	4.61e-05	CcSEcCtD
Boceprevir—Nausea—Prednisolone—hematologic cancer	8.06e-06	4.61e-05	CcSEcCtD
Boceprevir—Chest pain—Epirubicin—hematologic cancer	8.04e-06	4.6e-05	CcSEcCtD
Boceprevir—Arthralgia—Epirubicin—hematologic cancer	8.04e-06	4.6e-05	CcSEcCtD
Boceprevir—Myalgia—Epirubicin—hematologic cancer	8.04e-06	4.6e-05	CcSEcCtD
Boceprevir—Agitation—Doxorubicin—hematologic cancer	8.03e-06	4.59e-05	CcSEcCtD
Boceprevir—Anxiety—Epirubicin—hematologic cancer	8.02e-06	4.58e-05	CcSEcCtD
Boceprevir—Pruritus—Betamethasone—hematologic cancer	8.01e-06	4.58e-05	CcSEcCtD
Boceprevir—Pruritus—Dexamethasone—hematologic cancer	8.01e-06	4.58e-05	CcSEcCtD
Boceprevir—Skin disorder—Methotrexate—hematologic cancer	8e-06	4.58e-05	CcSEcCtD
Boceprevir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	7.99e-06	4.57e-05	CcSEcCtD
Boceprevir—Hyperhidrosis—Methotrexate—hematologic cancer	7.97e-06	4.55e-05	CcSEcCtD
Boceprevir—Discomfort—Epirubicin—hematologic cancer	7.95e-06	4.54e-05	CcSEcCtD
Boceprevir—Vomiting—Triamcinolone—hematologic cancer	7.93e-06	4.54e-05	CcSEcCtD
Boceprevir—Malaise—Doxorubicin—hematologic cancer	7.88e-06	4.51e-05	CcSEcCtD
Boceprevir—Rash—Triamcinolone—hematologic cancer	7.87e-06	4.5e-05	CcSEcCtD
Boceprevir—Dry mouth—Epirubicin—hematologic cancer	7.87e-06	4.5e-05	CcSEcCtD
Boceprevir—Dermatitis—Triamcinolone—hematologic cancer	7.86e-06	4.49e-05	CcSEcCtD
Boceprevir—Vertigo—Doxorubicin—hematologic cancer	7.85e-06	4.49e-05	CcSEcCtD
Boceprevir—Syncope—Doxorubicin—hematologic cancer	7.84e-06	4.48e-05	CcSEcCtD
Boceprevir—Urticaria—Prednisone—hematologic cancer	7.83e-06	4.48e-05	CcSEcCtD
Boceprevir—Leukopenia—Doxorubicin—hematologic cancer	7.83e-06	4.47e-05	CcSEcCtD
Boceprevir—Headache—Triamcinolone—hematologic cancer	7.82e-06	4.47e-05	CcSEcCtD
Boceprevir—Body temperature increased—Prednisone—hematologic cancer	7.79e-06	4.46e-05	CcSEcCtD
Boceprevir—Abdominal pain—Prednisone—hematologic cancer	7.79e-06	4.46e-05	CcSEcCtD
Boceprevir—Confusional state—Epirubicin—hematologic cancer	7.77e-06	4.44e-05	CcSEcCtD
Boceprevir—Diarrhoea—Betamethasone—hematologic cancer	7.75e-06	4.43e-05	CcSEcCtD
Boceprevir—Diarrhoea—Dexamethasone—hematologic cancer	7.75e-06	4.43e-05	CcSEcCtD
Boceprevir—Palpitations—Doxorubicin—hematologic cancer	7.73e-06	4.42e-05	CcSEcCtD
Boceprevir—Hypotension—Methotrexate—hematologic cancer	7.7e-06	4.4e-05	CcSEcCtD
Boceprevir—Loss of consciousness—Doxorubicin—hematologic cancer	7.68e-06	4.39e-05	CcSEcCtD
Boceprevir—Infection—Epirubicin—hematologic cancer	7.66e-06	4.38e-05	CcSEcCtD
Boceprevir—Cough—Doxorubicin—hematologic cancer	7.63e-06	4.36e-05	CcSEcCtD
Boceprevir—Shock—Epirubicin—hematologic cancer	7.59e-06	4.34e-05	CcSEcCtD
Boceprevir—Nervous system disorder—Epirubicin—hematologic cancer	7.56e-06	4.32e-05	CcSEcCtD
Boceprevir—Thrombocytopenia—Epirubicin—hematologic cancer	7.55e-06	4.32e-05	CcSEcCtD
Boceprevir—Hypertension—Doxorubicin—hematologic cancer	7.55e-06	4.31e-05	CcSEcCtD
Boceprevir—Tachycardia—Epirubicin—hematologic cancer	7.53e-06	4.3e-05	CcSEcCtD
Boceprevir—Musculoskeletal discomfort—Methotrexate—hematologic cancer	7.51e-06	4.29e-05	CcSEcCtD
Boceprevir—Skin disorder—Epirubicin—hematologic cancer	7.49e-06	4.28e-05	CcSEcCtD
Boceprevir—Dizziness—Dexamethasone—hematologic cancer	7.49e-06	4.28e-05	CcSEcCtD
Boceprevir—Dizziness—Betamethasone—hematologic cancer	7.49e-06	4.28e-05	CcSEcCtD
Boceprevir—Hyperhidrosis—Epirubicin—hematologic cancer	7.45e-06	4.26e-05	CcSEcCtD
Boceprevir—Insomnia—Methotrexate—hematologic cancer	7.45e-06	4.26e-05	CcSEcCtD
Boceprevir—Chest pain—Doxorubicin—hematologic cancer	7.44e-06	4.25e-05	CcSEcCtD
Boceprevir—Arthralgia—Doxorubicin—hematologic cancer	7.44e-06	4.25e-05	CcSEcCtD
Boceprevir—Myalgia—Doxorubicin—hematologic cancer	7.44e-06	4.25e-05	CcSEcCtD
Boceprevir—Anxiety—Doxorubicin—hematologic cancer	7.42e-06	4.24e-05	CcSEcCtD
Boceprevir—Nausea—Triamcinolone—hematologic cancer	7.41e-06	4.24e-05	CcSEcCtD
Boceprevir—Paraesthesia—Methotrexate—hematologic cancer	7.4e-06	4.23e-05	CcSEcCtD
Boceprevir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	7.39e-06	4.23e-05	CcSEcCtD
Boceprevir—Discomfort—Doxorubicin—hematologic cancer	7.35e-06	4.2e-05	CcSEcCtD
Boceprevir—Dyspnoea—Methotrexate—hematologic cancer	7.35e-06	4.2e-05	CcSEcCtD
Boceprevir—Dry mouth—Doxorubicin—hematologic cancer	7.28e-06	4.16e-05	CcSEcCtD
Boceprevir—Hypersensitivity—Prednisone—hematologic cancer	7.26e-06	4.15e-05	CcSEcCtD
Boceprevir—Dyspepsia—Methotrexate—hematologic cancer	7.25e-06	4.15e-05	CcSEcCtD
Boceprevir—Hypotension—Epirubicin—hematologic cancer	7.21e-06	4.12e-05	CcSEcCtD
Boceprevir—Vomiting—Betamethasone—hematologic cancer	7.2e-06	4.12e-05	CcSEcCtD
Boceprevir—Vomiting—Dexamethasone—hematologic cancer	7.2e-06	4.12e-05	CcSEcCtD
Boceprevir—Confusional state—Doxorubicin—hematologic cancer	7.19e-06	4.11e-05	CcSEcCtD
Boceprevir—Decreased appetite—Methotrexate—hematologic cancer	7.16e-06	4.09e-05	CcSEcCtD
Boceprevir—Rash—Betamethasone—hematologic cancer	7.14e-06	4.08e-05	CcSEcCtD
Boceprevir—Rash—Dexamethasone—hematologic cancer	7.14e-06	4.08e-05	CcSEcCtD
Boceprevir—Dermatitis—Dexamethasone—hematologic cancer	7.13e-06	4.08e-05	CcSEcCtD
Boceprevir—Dermatitis—Betamethasone—hematologic cancer	7.13e-06	4.08e-05	CcSEcCtD
Boceprevir—Gastrointestinal disorder—Methotrexate—hematologic cancer	7.11e-06	4.07e-05	CcSEcCtD
Boceprevir—Fatigue—Methotrexate—hematologic cancer	7.1e-06	4.06e-05	CcSEcCtD
Boceprevir—Headache—Dexamethasone—hematologic cancer	7.09e-06	4.05e-05	CcSEcCtD
Boceprevir—Headache—Betamethasone—hematologic cancer	7.09e-06	4.05e-05	CcSEcCtD
Boceprevir—Infection—Doxorubicin—hematologic cancer	7.09e-06	4.05e-05	CcSEcCtD
Boceprevir—Asthenia—Prednisone—hematologic cancer	7.07e-06	4.04e-05	CcSEcCtD
Boceprevir—Pain—Methotrexate—hematologic cancer	7.05e-06	4.03e-05	CcSEcCtD
Boceprevir—Musculoskeletal discomfort—Epirubicin—hematologic cancer	7.03e-06	4.02e-05	CcSEcCtD
Boceprevir—Shock—Doxorubicin—hematologic cancer	7.02e-06	4.01e-05	CcSEcCtD
Boceprevir—Nervous system disorder—Doxorubicin—hematologic cancer	7e-06	4e-05	CcSEcCtD
Boceprevir—Thrombocytopenia—Doxorubicin—hematologic cancer	6.99e-06	3.99e-05	CcSEcCtD
Boceprevir—Pruritus—Prednisone—hematologic cancer	6.98e-06	3.99e-05	CcSEcCtD
Boceprevir—Insomnia—Epirubicin—hematologic cancer	6.97e-06	3.99e-05	CcSEcCtD
Boceprevir—Tachycardia—Doxorubicin—hematologic cancer	6.96e-06	3.98e-05	CcSEcCtD
Boceprevir—Skin disorder—Doxorubicin—hematologic cancer	6.93e-06	3.96e-05	CcSEcCtD
Boceprevir—Paraesthesia—Epirubicin—hematologic cancer	6.92e-06	3.96e-05	CcSEcCtD
Boceprevir—Hyperhidrosis—Doxorubicin—hematologic cancer	6.9e-06	3.94e-05	CcSEcCtD
Boceprevir—Dyspnoea—Epirubicin—hematologic cancer	6.87e-06	3.93e-05	CcSEcCtD
Boceprevir—Feeling abnormal—Methotrexate—hematologic cancer	6.79e-06	3.88e-05	CcSEcCtD
Boceprevir—Dyspepsia—Epirubicin—hematologic cancer	6.79e-06	3.88e-05	CcSEcCtD
Boceprevir—Diarrhoea—Prednisone—hematologic cancer	6.75e-06	3.86e-05	CcSEcCtD
Boceprevir—Gastrointestinal pain—Methotrexate—hematologic cancer	6.74e-06	3.85e-05	CcSEcCtD
Boceprevir—Nausea—Betamethasone—hematologic cancer	6.72e-06	3.84e-05	CcSEcCtD
Boceprevir—Nausea—Dexamethasone—hematologic cancer	6.72e-06	3.84e-05	CcSEcCtD
Boceprevir—Decreased appetite—Epirubicin—hematologic cancer	6.7e-06	3.83e-05	CcSEcCtD
Boceprevir—Hypotension—Doxorubicin—hematologic cancer	6.67e-06	3.81e-05	CcSEcCtD
Boceprevir—Gastrointestinal disorder—Epirubicin—hematologic cancer	6.66e-06	3.81e-05	CcSEcCtD
Boceprevir—Fatigue—Epirubicin—hematologic cancer	6.65e-06	3.8e-05	CcSEcCtD
Boceprevir—Pain—Epirubicin—hematologic cancer	6.59e-06	3.77e-05	CcSEcCtD
Boceprevir—Constipation—Epirubicin—hematologic cancer	6.59e-06	3.77e-05	CcSEcCtD
Boceprevir—Urticaria—Methotrexate—hematologic cancer	6.55e-06	3.74e-05	CcSEcCtD
Boceprevir—Dizziness—Prednisone—hematologic cancer	6.52e-06	3.73e-05	CcSEcCtD
Boceprevir—Body temperature increased—Methotrexate—hematologic cancer	6.51e-06	3.72e-05	CcSEcCtD
Boceprevir—Abdominal pain—Methotrexate—hematologic cancer	6.51e-06	3.72e-05	CcSEcCtD
Boceprevir—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	6.5e-06	3.72e-05	CcSEcCtD
Boceprevir—Insomnia—Doxorubicin—hematologic cancer	6.45e-06	3.69e-05	CcSEcCtD
Boceprevir—Paraesthesia—Doxorubicin—hematologic cancer	6.41e-06	3.66e-05	CcSEcCtD
Boceprevir—Dyspnoea—Doxorubicin—hematologic cancer	6.36e-06	3.64e-05	CcSEcCtD
Boceprevir—Feeling abnormal—Epirubicin—hematologic cancer	6.35e-06	3.63e-05	CcSEcCtD
Boceprevir—CTSK—Immune System—MAPK3—hematologic cancer	6.35e-06	6.55e-05	CbGpPWpGaD
Boceprevir—CTSS—Immune System—JUN—hematologic cancer	6.33e-06	6.53e-05	CbGpPWpGaD
Boceprevir—CTSL—Immune System—PIK3CA—hematologic cancer	6.33e-06	6.53e-05	CbGpPWpGaD
Boceprevir—CTSV—Immune System—PIK3CA—hematologic cancer	6.33e-06	6.53e-05	CbGpPWpGaD
Boceprevir—Gastrointestinal pain—Epirubicin—hematologic cancer	6.31e-06	3.6e-05	CcSEcCtD
Boceprevir—Dyspepsia—Doxorubicin—hematologic cancer	6.28e-06	3.59e-05	CcSEcCtD
Boceprevir—ABCB1—Transmembrane transport of small molecules—SLC22A1—hematologic cancer	6.27e-06	6.47e-05	CbGpPWpGaD
Boceprevir—Vomiting—Prednisone—hematologic cancer	6.27e-06	3.58e-05	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—PIK3CB—hematologic cancer	6.24e-06	6.44e-05	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—MTOR—hematologic cancer	6.24e-06	6.44e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Biological oxidations—GSTP1—hematologic cancer	6.22e-06	6.42e-05	CbGpPWpGaD
Boceprevir—Rash—Prednisone—hematologic cancer	6.22e-06	3.55e-05	CcSEcCtD
Boceprevir—Dermatitis—Prednisone—hematologic cancer	6.21e-06	3.55e-05	CcSEcCtD
Boceprevir—Decreased appetite—Doxorubicin—hematologic cancer	6.2e-06	3.55e-05	CcSEcCtD
Boceprevir—ABCB1—Metabolism—DCK—hematologic cancer	6.19e-06	6.38e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—ASNS—hematologic cancer	6.19e-06	6.38e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—B3GAT1—hematologic cancer	6.19e-06	6.38e-05	CbGpPWpGaD
Boceprevir—Headache—Prednisone—hematologic cancer	6.18e-06	3.53e-05	CcSEcCtD
Boceprevir—Gastrointestinal disorder—Doxorubicin—hematologic cancer	6.16e-06	3.52e-05	CcSEcCtD
Boceprevir—Fatigue—Doxorubicin—hematologic cancer	6.15e-06	3.52e-05	CcSEcCtD
Boceprevir—CTSS—Immune System—CDKN1A—hematologic cancer	6.14e-06	6.33e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metapathway biotransformation—GSTP1—hematologic cancer	6.14e-06	6.33e-05	CbGpPWpGaD
Boceprevir—Urticaria—Epirubicin—hematologic cancer	6.13e-06	3.5e-05	CcSEcCtD
Boceprevir—CTSS—Immune System—PTEN—hematologic cancer	6.12e-06	6.32e-05	CbGpPWpGaD
Boceprevir—Constipation—Doxorubicin—hematologic cancer	6.1e-06	3.49e-05	CcSEcCtD
Boceprevir—Pain—Doxorubicin—hematologic cancer	6.1e-06	3.49e-05	CcSEcCtD
Boceprevir—Body temperature increased—Epirubicin—hematologic cancer	6.1e-06	3.48e-05	CcSEcCtD
Boceprevir—Abdominal pain—Epirubicin—hematologic cancer	6.1e-06	3.48e-05	CcSEcCtD
Boceprevir—Hypersensitivity—Methotrexate—hematologic cancer	6.07e-06	3.47e-05	CcSEcCtD
Boceprevir—CTSS—Innate Immune System—AKT1—hematologic cancer	6.06e-06	6.25e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—MTAP—hematologic cancer	6.04e-06	6.23e-05	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—CREB1—hematologic cancer	6.03e-06	6.22e-05	CbGpPWpGaD
Boceprevir—CTSS—Immune System—MAPK8—hematologic cancer	5.99e-06	6.18e-05	CbGpPWpGaD
Boceprevir—ABCB1—Transmembrane transport of small molecules—NUP98—hematologic cancer	5.92e-06	6.11e-05	CbGpPWpGaD
Boceprevir—Asthenia—Methotrexate—hematologic cancer	5.91e-06	3.38e-05	CcSEcCtD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—hematologic cancer	5.9e-06	6.09e-05	CbGpPWpGaD
Boceprevir—Feeling abnormal—Doxorubicin—hematologic cancer	5.88e-06	3.36e-05	CcSEcCtD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—hematologic cancer	5.87e-06	6.06e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—HDC—hematologic cancer	5.86e-06	6.05e-05	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—CDKN1B—hematologic cancer	5.86e-06	6.04e-05	CbGpPWpGaD
Boceprevir—Nausea—Prednisone—hematologic cancer	5.86e-06	3.35e-05	CcSEcCtD
Boceprevir—CTSL—Immune System—HRAS—hematologic cancer	5.86e-06	6.04e-05	CbGpPWpGaD
Boceprevir—CTSV—Immune System—HRAS—hematologic cancer	5.86e-06	6.04e-05	CbGpPWpGaD
Boceprevir—CTSS—Immune System—EP300—hematologic cancer	5.84e-06	6.02e-05	CbGpPWpGaD
Boceprevir—Gastrointestinal pain—Doxorubicin—hematologic cancer	5.83e-06	3.34e-05	CcSEcCtD
Boceprevir—Pruritus—Methotrexate—hematologic cancer	5.83e-06	3.33e-05	CcSEcCtD
Boceprevir—CTSS—Adaptive Immune System—AKT1—hematologic cancer	5.82e-06	6e-05	CbGpPWpGaD
Boceprevir—ABCB1—Transmembrane transport of small molecules—ADCY7—hematologic cancer	5.75e-06	5.93e-05	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—CASP3—hematologic cancer	5.74e-06	5.92e-05	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—IL2—hematologic cancer	5.73e-06	5.91e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Biological oxidations—GSTM1—hematologic cancer	5.72e-06	5.9e-05	CbGpPWpGaD
Boceprevir—CTSK—Immune System—KRAS—hematologic cancer	5.71e-06	5.89e-05	CbGpPWpGaD
Boceprevir—ABCB1—Transmembrane transport of small molecules—NUP214—hematologic cancer	5.71e-06	5.89e-05	CbGpPWpGaD
Boceprevir—Hypersensitivity—Epirubicin—hematologic cancer	5.68e-06	3.25e-05	CcSEcCtD
Boceprevir—CTSS—Immune System—SRC—hematologic cancer	5.68e-06	5.86e-05	CbGpPWpGaD
Boceprevir—Urticaria—Doxorubicin—hematologic cancer	5.67e-06	3.24e-05	CcSEcCtD
Boceprevir—ABCB1—HIF-1-alpha transcription factor network—AKT1—hematologic cancer	5.66e-06	5.84e-05	CbGpPWpGaD
Boceprevir—Abdominal pain—Doxorubicin—hematologic cancer	5.64e-06	3.22e-05	CcSEcCtD
Boceprevir—Body temperature increased—Doxorubicin—hematologic cancer	5.64e-06	3.22e-05	CcSEcCtD
Boceprevir—CYP3A4—Metapathway biotransformation—GSTM1—hematologic cancer	5.64e-06	5.82e-05	CbGpPWpGaD
Boceprevir—Diarrhoea—Methotrexate—hematologic cancer	5.64e-06	3.22e-05	CcSEcCtD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—MAP2K1—hematologic cancer	5.61e-06	5.78e-05	CbGpPWpGaD
Boceprevir—CTSV—Immune System—IL6—hematologic cancer	5.6e-06	5.78e-05	CbGpPWpGaD
Boceprevir—CTSL—Immune System—IL6—hematologic cancer	5.6e-06	5.78e-05	CbGpPWpGaD
Boceprevir—ABCB1—Transmembrane transport of small molecules—ABCG2—hematologic cancer	5.59e-06	5.77e-05	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—CCND1—hematologic cancer	5.59e-06	5.76e-05	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—JUN—hematologic cancer	5.58e-06	5.75e-05	CbGpPWpGaD
Boceprevir—Asthenia—Epirubicin—hematologic cancer	5.53e-06	3.16e-05	CcSEcCtD
Boceprevir—CTSS—Immune System—STAT3—hematologic cancer	5.47e-06	5.65e-05	CbGpPWpGaD
Boceprevir—CTSS—Immune System—NRAS—hematologic cancer	5.46e-06	5.63e-05	CbGpPWpGaD
Boceprevir—Pruritus—Epirubicin—hematologic cancer	5.46e-06	3.12e-05	CcSEcCtD
Boceprevir—Dizziness—Methotrexate—hematologic cancer	5.45e-06	3.11e-05	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—CDKN1A—hematologic cancer	5.4e-06	5.58e-05	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—PTEN—hematologic cancer	5.39e-06	5.56e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—FHL2—hematologic cancer	5.39e-06	5.56e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—CDA—hematologic cancer	5.36e-06	5.53e-05	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—FGF2—hematologic cancer	5.33e-06	5.5e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—AGRN—hematologic cancer	5.28e-06	5.45e-05	CbGpPWpGaD
Boceprevir—Diarrhoea—Epirubicin—hematologic cancer	5.28e-06	3.02e-05	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—MAPK8—hematologic cancer	5.28e-06	5.44e-05	CbGpPWpGaD
Boceprevir—Hypersensitivity—Doxorubicin—hematologic cancer	5.26e-06	3.01e-05	CcSEcCtD
Boceprevir—CTSK—Immune System—PIK3CA—hematologic cancer	5.24e-06	5.41e-05	CbGpPWpGaD
Boceprevir—Vomiting—Methotrexate—hematologic cancer	5.24e-06	3e-05	CcSEcCtD
Boceprevir—CTSS—Immune System—MAPK3—hematologic cancer	5.23e-06	5.4e-05	CbGpPWpGaD
Boceprevir—Rash—Methotrexate—hematologic cancer	5.2e-06	2.97e-05	CcSEcCtD
Boceprevir—Dermatitis—Methotrexate—hematologic cancer	5.19e-06	2.97e-05	CcSEcCtD
Boceprevir—CTSV—Immune System—AKT1—hematologic cancer	5.17e-06	5.33e-05	CbGpPWpGaD
Boceprevir—CTSL—Immune System—AKT1—hematologic cancer	5.17e-06	5.33e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—PC—hematologic cancer	5.16e-06	5.33e-05	CbGpPWpGaD
Boceprevir—Headache—Methotrexate—hematologic cancer	5.16e-06	2.95e-05	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—EP300—hematologic cancer	5.14e-06	5.31e-05	CbGpPWpGaD
Boceprevir—Asthenia—Doxorubicin—hematologic cancer	5.12e-06	2.93e-05	CcSEcCtD
Boceprevir—Dizziness—Epirubicin—hematologic cancer	5.1e-06	2.92e-05	CcSEcCtD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—hematologic cancer	5.06e-06	5.22e-05	CbGpPWpGaD
Boceprevir—Pruritus—Doxorubicin—hematologic cancer	5.05e-06	2.89e-05	CcSEcCtD
Boceprevir—CYP3A5—Metabolism—IDH2—hematologic cancer	5.01e-06	5.17e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—HMMR—hematologic cancer	5.01e-06	5.17e-05	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—SRC—hematologic cancer	5e-06	5.16e-05	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—hematologic cancer	4.99e-06	5.15e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—SLC35B2—hematologic cancer	4.99e-06	5.14e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—GBA—hematologic cancer	4.99e-06	5.14e-05	CbGpPWpGaD
Boceprevir—ABCB1—Transmembrane transport of small molecules—TFRC—hematologic cancer	4.98e-06	5.14e-05	CbGpPWpGaD
Boceprevir—Vomiting—Epirubicin—hematologic cancer	4.9e-06	2.8e-05	CcSEcCtD
Boceprevir—Nausea—Methotrexate—hematologic cancer	4.89e-06	2.8e-05	CcSEcCtD
Boceprevir—Diarrhoea—Doxorubicin—hematologic cancer	4.88e-06	2.79e-05	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—VEGFA—hematologic cancer	4.87e-06	5.02e-05	CbGpPWpGaD
Boceprevir—Rash—Epirubicin—hematologic cancer	4.86e-06	2.78e-05	CcSEcCtD
Boceprevir—Dermatitis—Epirubicin—hematologic cancer	4.86e-06	2.78e-05	CcSEcCtD
Boceprevir—CTSK—Immune System—HRAS—hematologic cancer	4.85e-06	5.01e-05	CbGpPWpGaD
Boceprevir—Headache—Epirubicin—hematologic cancer	4.83e-06	2.76e-05	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—STAT3—hematologic cancer	4.82e-06	4.98e-05	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—NRAS—hematologic cancer	4.81e-06	4.96e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—FTCD—hematologic cancer	4.77e-06	4.92e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—PHYH—hematologic cancer	4.77e-06	4.92e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—GMPS—hematologic cancer	4.77e-06	4.92e-05	CbGpPWpGaD
Boceprevir—Dizziness—Doxorubicin—hematologic cancer	4.72e-06	2.7e-05	CcSEcCtD
Boceprevir—CYP3A5—Metabolism—ARNTL—hematologic cancer	4.71e-06	4.86e-05	CbGpPWpGaD
Boceprevir—CTSS—Immune System—KRAS—hematologic cancer	4.7e-06	4.85e-05	CbGpPWpGaD
Boceprevir—CTSK—Immune System—IL6—hematologic cancer	4.64e-06	4.79e-05	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—MAPK3—hematologic cancer	4.61e-06	4.75e-05	CbGpPWpGaD
Boceprevir—Nausea—Epirubicin—hematologic cancer	4.58e-06	2.62e-05	CcSEcCtD
Boceprevir—CYP3A5—Metabolism—CA9—hematologic cancer	4.58e-06	4.72e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—ACP5—hematologic cancer	4.58e-06	4.72e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—MTAP—hematologic cancer	4.56e-06	4.7e-05	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—hematologic cancer	4.56e-06	4.7e-05	CbGpPWpGaD
Boceprevir—Vomiting—Doxorubicin—hematologic cancer	4.54e-06	2.59e-05	CcSEcCtD
Boceprevir—CYP3A5—Metabolism—NCOR2—hematologic cancer	4.52e-06	4.66e-05	CbGpPWpGaD
Boceprevir—Rash—Doxorubicin—hematologic cancer	4.5e-06	2.57e-05	CcSEcCtD
Boceprevir—Dermatitis—Doxorubicin—hematologic cancer	4.49e-06	2.57e-05	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—MYC—hematologic cancer	4.48e-06	4.62e-05	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—TGFB1—hematologic cancer	4.47e-06	4.61e-05	CbGpPWpGaD
Boceprevir—Headache—Doxorubicin—hematologic cancer	4.47e-06	2.56e-05	CcSEcCtD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—hematologic cancer	4.47e-06	4.61e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—SMPD3—hematologic cancer	4.36e-06	4.5e-05	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—hematologic cancer	4.35e-06	4.48e-05	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—hematologic cancer	4.34e-06	4.47e-05	CbGpPWpGaD
Boceprevir—CTSS—Immune System—PIK3CA—hematologic cancer	4.32e-06	4.46e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—IDH1—hematologic cancer	4.31e-06	4.44e-05	CbGpPWpGaD
Boceprevir—CTSK—Immune System—AKT1—hematologic cancer	4.28e-06	4.42e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—TXN—hematologic cancer	4.26e-06	4.39e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—GSTO1—hematologic cancer	4.26e-06	4.39e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—ABCC3—hematologic cancer	4.26e-06	4.39e-05	CbGpPWpGaD
Boceprevir—Nausea—Doxorubicin—hematologic cancer	4.24e-06	2.42e-05	CcSEcCtD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—hematologic cancer	4.2e-06	4.34e-05	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—hematologic cancer	4.2e-06	4.33e-05	CbGpPWpGaD
Boceprevir—ABCB1—Transmembrane transport of small molecules—CYCS—hematologic cancer	4.18e-06	4.32e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—SPHK1—hematologic cancer	4.17e-06	4.3e-05	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—KRAS—hematologic cancer	4.14e-06	4.27e-05	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—hematologic cancer	4.1e-06	4.23e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—FHL2—hematologic cancer	4.06e-06	4.19e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—UGT1A1—hematologic cancer	4e-06	4.13e-05	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—hematologic cancer	4e-06	4.13e-05	CbGpPWpGaD
Boceprevir—CTSS—Immune System—HRAS—hematologic cancer	4e-06	4.12e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—AGRN—hematologic cancer	3.99e-06	4.11e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—CRABP1—hematologic cancer	3.89e-06	4.02e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—SLC22A1—hematologic cancer	3.89e-06	4.02e-05	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—hematologic cancer	3.89e-06	4.01e-05	CbGpPWpGaD
Boceprevir—CTSS—Immune System—IL6—hematologic cancer	3.82e-06	3.95e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—DCK—hematologic cancer	3.81e-06	3.93e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—B3GAT1—hematologic cancer	3.81e-06	3.93e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—ASNS—hematologic cancer	3.81e-06	3.93e-05	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—PIK3CA—hematologic cancer	3.8e-06	3.92e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—ALOX5—hematologic cancer	3.8e-06	3.92e-05	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—hematologic cancer	3.79e-06	3.91e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—IDH2—hematologic cancer	3.78e-06	3.9e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—HMMR—hematologic cancer	3.78e-06	3.9e-05	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—TP53—hematologic cancer	3.68e-06	3.8e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—NUP98—hematologic cancer	3.68e-06	3.79e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—HDC—hematologic cancer	3.61e-06	3.73e-05	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—hematologic cancer	3.58e-06	3.7e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—ADCY7—hematologic cancer	3.57e-06	3.68e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—NCOA3—hematologic cancer	3.57e-06	3.68e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—ARNTL—hematologic cancer	3.55e-06	3.67e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—NUP214—hematologic cancer	3.54e-06	3.65e-05	CbGpPWpGaD
Boceprevir—CTSS—Immune System—AKT1—hematologic cancer	3.53e-06	3.64e-05	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—HRAS—hematologic cancer	3.52e-06	3.63e-05	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—hematologic cancer	3.49e-06	3.6e-05	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—hematologic cancer	3.48e-06	3.59e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—ABCG2—hematologic cancer	3.47e-06	3.58e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—MTR—hematologic cancer	3.47e-06	3.58e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—CA9—hematologic cancer	3.46e-06	3.57e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—ACP5—hematologic cancer	3.46e-06	3.57e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—NCOR2—hematologic cancer	3.41e-06	3.52e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—ENO2—hematologic cancer	3.4e-06	3.51e-05	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—IL6—hematologic cancer	3.37e-06	3.48e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—CDA—hematologic cancer	3.3e-06	3.41e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—GSTT1—hematologic cancer	3.3e-06	3.41e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—IDH1—hematologic cancer	3.25e-06	3.35e-05	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—hematologic cancer	3.25e-06	3.35e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—SDC1—hematologic cancer	3.23e-06	3.33e-05	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—hematologic cancer	3.22e-06	3.32e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—ABCC3—hematologic cancer	3.21e-06	3.31e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—TXN—hematologic cancer	3.21e-06	3.31e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—GSTO1—hematologic cancer	3.21e-06	3.31e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—PC—hematologic cancer	3.18e-06	3.28e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—SPHK1—hematologic cancer	3.14e-06	3.24e-05	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—AKT1—hematologic cancer	3.11e-06	3.21e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—SLC35B2—hematologic cancer	3.07e-06	3.17e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—GBA—hematologic cancer	3.07e-06	3.17e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—UGT1A1—hematologic cancer	3.02e-06	3.12e-05	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—hematologic cancer	2.96e-06	3.05e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—CRABP1—hematologic cancer	2.94e-06	3.03e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—SLC22A1—hematologic cancer	2.94e-06	3.03e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—ALOX5—hematologic cancer	2.86e-06	2.95e-05	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—hematologic cancer	2.86e-06	2.95e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—MTAP—hematologic cancer	2.81e-06	2.9e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—NUP98—hematologic cancer	2.77e-06	2.86e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—CD44—hematologic cancer	2.74e-06	2.83e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—NQO1—hematologic cancer	2.74e-06	2.83e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—ADCY7—hematologic cancer	2.69e-06	2.78e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—NCOA3—hematologic cancer	2.69e-06	2.78e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—NUP214—hematologic cancer	2.67e-06	2.76e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—MTR—hematologic cancer	2.62e-06	2.7e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—ABCG2—hematologic cancer	2.62e-06	2.7e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—CYCS—hematologic cancer	2.6e-06	2.68e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—HSP90AA1—hematologic cancer	2.58e-06	2.66e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—ENO2—hematologic cancer	2.57e-06	2.65e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—FHL2—hematologic cancer	2.5e-06	2.58e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—GSTT1—hematologic cancer	2.49e-06	2.57e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—AGRN—hematologic cancer	2.46e-06	2.53e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—SDC1—hematologic cancer	2.43e-06	2.51e-05	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—hematologic cancer	2.42e-06	2.49e-05	CbGpPWpGaD
Boceprevir—ABCB1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	2.33e-06	2.41e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—IDH2—hematologic cancer	2.33e-06	2.4e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—HMMR—hematologic cancer	2.33e-06	2.4e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—GSTP1—hematologic cancer	2.29e-06	2.36e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—ARNTL—hematologic cancer	2.19e-06	2.26e-05	CbGpPWpGaD
Boceprevir—ABCB1—Transmembrane transport of small molecules—ALB—hematologic cancer	2.18e-06	2.25e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—ABCB1—hematologic cancer	2.17e-06	2.23e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—CA9—hematologic cancer	2.13e-06	2.2e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—ACP5—hematologic cancer	2.13e-06	2.2e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—GSTM1—hematologic cancer	2.1e-06	2.17e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—NCOR1—hematologic cancer	2.1e-06	2.17e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—NCOR2—hematologic cancer	2.1e-06	2.17e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—NQO1—hematologic cancer	2.07e-06	2.14e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—CD44—hematologic cancer	2.07e-06	2.14e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—IDH1—hematologic cancer	2e-06	2.07e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—GSTO1—hematologic cancer	1.98e-06	2.04e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—TXN—hematologic cancer	1.98e-06	2.04e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—ABCC3—hematologic cancer	1.98e-06	2.04e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—CYCS—hematologic cancer	1.96e-06	2.02e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—HSP90AA1—hematologic cancer	1.95e-06	2.01e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—SPHK1—hematologic cancer	1.94e-06	2e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—UGT1A1—hematologic cancer	1.86e-06	1.92e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—MTHFR—hematologic cancer	1.86e-06	1.92e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—CRABP1—hematologic cancer	1.81e-06	1.87e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—SLC22A1—hematologic cancer	1.81e-06	1.87e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—ALOX5—hematologic cancer	1.76e-06	1.82e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—GSTP1—hematologic cancer	1.73e-06	1.78e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—NUP98—hematologic cancer	1.71e-06	1.76e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—NCOA3—hematologic cancer	1.66e-06	1.71e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—ADCY7—hematologic cancer	1.66e-06	1.71e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—NUP214—hematologic cancer	1.65e-06	1.7e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—ABCG2—hematologic cancer	1.61e-06	1.66e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—MTR—hematologic cancer	1.61e-06	1.66e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—GSTM1—hematologic cancer	1.59e-06	1.64e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—NCOR1—hematologic cancer	1.59e-06	1.64e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—ENO2—hematologic cancer	1.58e-06	1.63e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—PIK3CG—hematologic cancer	1.56e-06	1.61e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—GSTT1—hematologic cancer	1.53e-06	1.58e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—SDC1—hematologic cancer	1.5e-06	1.55e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—CREBBP—hematologic cancer	1.45e-06	1.49e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—MTHFR—hematologic cancer	1.4e-06	1.45e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—PIK3CD—hematologic cancer	1.37e-06	1.42e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—ALB—hematologic cancer	1.36e-06	1.4e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—PIK3R1—hematologic cancer	1.3e-06	1.34e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—CD44—hematologic cancer	1.28e-06	1.32e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—NQO1—hematologic cancer	1.28e-06	1.32e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—CYCS—hematologic cancer	1.21e-06	1.25e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	1.2e-06	1.24e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—PIK3CB—hematologic cancer	1.2e-06	1.23e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—PIK3CG—hematologic cancer	1.18e-06	1.22e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—CREBBP—hematologic cancer	1.09e-06	1.13e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—GSTP1—hematologic cancer	1.06e-06	1.1e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—PIK3CD—hematologic cancer	1.04e-06	1.07e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—PTEN—hematologic cancer	1.03e-06	1.07e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—ALB—hematologic cancer	1.02e-06	1.05e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—ABCB1—hematologic cancer	1.01e-06	1.04e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—EP300—hematologic cancer	9.86e-07	1.02e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—PIK3R1—hematologic cancer	9.78e-07	1.01e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—NCOR1—hematologic cancer	9.78e-07	1.01e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—GSTM1—hematologic cancer	9.78e-07	1.01e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—PIK3CB—hematologic cancer	9.03e-07	9.31e-06	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—MTHFR—hematologic cancer	8.64e-07	8.91e-06	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—PTEN—hematologic cancer	7.8e-07	8.05e-06	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—EP300—hematologic cancer	7.44e-07	7.68e-06	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—PIK3CA—hematologic cancer	7.29e-07	7.52e-06	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—PIK3CG—hematologic cancer	7.26e-07	7.49e-06	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—CREBBP—hematologic cancer	6.73e-07	6.94e-06	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—PIK3CD—hematologic cancer	6.38e-07	6.58e-06	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—ALB—hematologic cancer	6.3e-07	6.5e-06	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—PIK3R1—hematologic cancer	6.03e-07	6.22e-06	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—AKT1—hematologic cancer	5.96e-07	6.15e-06	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—PIK3CB—hematologic cancer	5.56e-07	5.74e-06	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—PIK3CA—hematologic cancer	5.5e-07	5.68e-06	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—PTEN—hematologic cancer	4.81e-07	4.96e-06	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—EP300—hematologic cancer	4.58e-07	4.73e-06	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—AKT1—hematologic cancer	4.5e-07	4.64e-06	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—PIK3CA—hematologic cancer	3.39e-07	3.5e-06	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—AKT1—hematologic cancer	2.77e-07	2.86e-06	CbGpPWpGaD
